PMC:7461420 / 31361-31721
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T172 | 264-269 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T179 | 67-71 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T180 | 241-245 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T355 | 0-1 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T356 | 19-22 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T357 | 154-155 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T358 | 176-178 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
| T359 | 190-191 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T360 | 264-269 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T361 | 273-274 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T362 | 315-317 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
| T363 | 321-322 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T281 | 202-211 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 994 | 67-77 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
| 995 | 241-249 | Species | denotes | SARS‐CoV | Tax:694009 |
| 996 | 190-211 | Gene | denotes | a cathepsin inhibitor | Gene:6783 |
| 997 | 183-188 | Chemical | denotes | E‐64d |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T292 | 79-213 | Sentence | denotes | Pöhlmann et al. reported the attainment of full inhibition efficiency with a combination of both 18 and E‐64d (a cathepsin inhibitor). |
| T293 | 214-357 | Sentence | denotes | Both studies indicate that SARS‐CoV‐1 and 2 enter cells in a similar manner showing the potential of 18 as a candidate for further development. |
| T294 | 358-360 | Sentence | denotes | 15 |